{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T14:59:01Z","timestamp":1793285941499,"version":"4.5.0"},"reference-count":22,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2012,12,1]],"date-time":"2012-12-01T00:00:00Z","timestamp":1354320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Parkinsonism & Related Disorders"],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1016\/j.parkreldis.2012.06.005","type":"journal-article","created":{"date-parts":[[2012,7,10]],"date-time":"2012-07-10T00:45:15Z","timestamp":1341881115000},"page":"1079-1083","source":"Crossref","is-referenced-by-count":56,"title":["Effects of dopamine agonist dose and gender on the prognosis of impulse control disorders in Parkinson's disease"],"prefix":"10.1016","volume":"18","author":[{"given":"Juho","family":"Joutsa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsti","family":"Martikainen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tero","family":"Vahlberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valtteri","family":"Kaasinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.parkreldis.2012.06.005_bib1","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/j.1360-0443.2010.03218.x","article-title":"Impulse control disorders in patients with Parkinson's disease receiving dopamine replacement therapy: evidence and implications for the addictions field","volume":"106","author":"Ambermoon","year":"2011","journal-title":"Addiction"},{"key":"10.1016\/j.parkreldis.2012.06.005_bib2","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/1471-2377-11-117","article-title":"Frequency of impulse control behaviours associated with dopaminergic therapy in restless legs syndrome","volume":"11","author":"Voon","year":"2011","journal-title":"BMC Neurol"},{"key":"10.1016\/j.parkreldis.2012.06.005_bib3","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/mds.21770","article-title":"Long-term follow-up of impulse control disorders in Parkinson's disease","volume":"23","author":"Mamikonyan","year":"2008","journal-title":"Mov Disord"},{"key":"10.1016\/j.parkreldis.2012.06.005_bib4","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1002\/mds.22824","article-title":"Clinical follow up of pathological gambling in Parkinson's disease in the West Scotland study","volume":"24","author":"Macphee","year":"2009","journal-title":"Mov Disord"},{"key":"10.1016\/j.parkreldis.2012.06.005_bib5","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.parkreldis.2010.02.006","article-title":"Long term follow-up of Parkinson's disease patients with impulse control disorders","volume":"16","author":"Sohtao\u011flu","year":"2010","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.parkreldis.2012.06.005_bib6","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1017\/S0317167100010489","article-title":"Outcomes of patients with Parkinson disease and pathological gambling","volume":"37","author":"Bharmal","year":"2010","journal-title":"Can J Neurol Sci"},{"key":"10.1016\/j.parkreldis.2012.06.005_bib7","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1016\/j.jocn.2007.01.009","article-title":"Risk factors for pathologic gambling and other compulsions among Parkinson's disease patients taking dopamine agonists","volume":"14","author":"Singh","year":"2007","journal-title":"J\u00a0Clin Neurosci"},{"key":"10.1016\/j.parkreldis.2012.06.005_bib8","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1002\/ana.22164","article-title":"Amantadine use associated with impulse control disorders in Parkinson disease in cross-sectional study","volume":"68","author":"Weintraub","year":"2010","journal-title":"Ann Neurol"},{"key":"10.1016\/j.parkreldis.2012.06.005_bib9","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1001\/archneurol.2010.65","article-title":"Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients","volume":"67","author":"Weintraub","year":"2010","journal-title":"Arch Neurol"},{"key":"10.1016\/j.parkreldis.2012.06.005_bib10","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.physbeh.2011.04.055","article-title":"Pathological behaviors provoked by dopamine agonist therapy of Parkinson's disease","volume":"104","author":"Ahlskog","year":"2011","journal-title":"Physiol Behav"},{"key":"10.1016\/j.parkreldis.2012.06.005_bib11","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.parkreldis.2011.09.007","article-title":"Impulse control disorders and depression in Finnish patients with Parkinson's disease","volume":"18","author":"Joutsa","year":"2012","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.parkreldis.2012.06.005_bib12","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1001\/archneurol.2009.294","article-title":"Dopamine agonist withdrawal syndrome in Parkinson disease","volume":"67","author":"Rabinak","year":"2010","journal-title":"Arch Neurol"},{"key":"10.1016\/j.parkreldis.2012.06.005_bib13","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1002\/mds.23429","article-title":"Systematic review of levodopa dose equivalency reporting in Parkinson's disease","volume":"25","author":"Tomlinson","year":"2010","journal-title":"Mov Disord"},{"key":"10.1016\/j.parkreldis.2012.06.005_bib14","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1002\/mds.22571","article-title":"Validation of the questionnaire for impulsive-compulsive disorders in Parkinson's disease","volume":"24","author":"Weintraub","year":"2009","journal-title":"Mov Disord"},{"key":"10.1016\/j.parkreldis.2012.06.005_bib15","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.parkreldis.2010.11.015","volume":"17","author":"Papay","year":"2011","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.parkreldis.2012.06.005_bib16","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1002\/mds.21611","article-title":"Pathological gambling in Parkinson's disease: risk factors and differences from dopamine dysregulation. An analysis of published case series","volume":"22","author":"Gallagher","year":"2007","journal-title":"Mov Disord"},{"key":"10.1016\/j.parkreldis.2012.06.005_bib17","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1001\/archneur.62.9.noc50009","article-title":"Pathological gambling caused by drugs used to treat Parkinson disease","volume":"62","author":"Dodd","year":"2005","journal-title":"Arch Neurol"},{"key":"10.1016\/j.parkreldis.2012.06.005_bib18","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1002\/ana.22356","article-title":"Impulse control disorders in Parkinson disease: a multicenter case\u2013control study","volume":"69","author":"Voon","year":"2011","journal-title":"Ann Neurol"},{"key":"10.1016\/j.parkreldis.2012.06.005_bib19","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.parkreldis.2005.06.005","article-title":"Pathological hypersexuality predominantly linked to adjuvant dopamine agonist therapy in Parkinson's disease and multiple system atrophy","volume":"11","author":"Klos","year":"2005","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.parkreldis.2012.06.005_bib20","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1002\/mds.23763","article-title":"Quality of life in young- compared with late-onset Parkinson's disease","volume":"26","author":"Knipe","year":"2011","journal-title":"Mov Disord"},{"key":"10.1016\/j.parkreldis.2012.06.005_bib21","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3109\/00207454.2011.633722","article-title":"Addiction-like manifestations and Parkinson's disease: a large single center 9-year experience","volume":"122","author":"Limotai","year":"2012","journal-title":"Int J Neurosci"},{"key":"10.1016\/j.parkreldis.2012.06.005_bib22","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1002\/mds.21333","article-title":"Depression rating scales in Parkinson\u2019s disease: critique and recommendations","volume":"22","author":"Schrag","year":"2007","journal-title":"Mov Disord"}],"container-title":["Parkinsonism & Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S135380201200243X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S135380201200243X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,7,10]],"date-time":"2020-07-10T13:40:10Z","timestamp":1594388410000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S135380201200243X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12]]},"references-count":22,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["S135380201200243X"],"URL":"https:\/\/doi.org\/10.1016\/j.parkreldis.2012.06.005","relation":{},"ISSN":["1353-8020"],"issn-type":[{"value":"1353-8020","type":"print"}],"subject":[],"published":{"date-parts":[[2012,12]]}}}